Roche

European Pharmaceutical Review | May 04, 2017

Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA)....

Roche | May 10, 2017

Roche’s immunotherapy Tecentriq has failed to significantly improve overall survival compared to chemotherapy in pre-treated patients with advanced bladder cancer, marking a major setback for the drug....

Roche | May 14, 2017

Let’s hark back to the Nineties. The HIV-AIDS epidemic was spreading across Africa, leaving thousands dead, in spite of the existence of anti-retroviral drugs (ARVs)....

Roche | June 12, 2017

Essentially, this means that patients will have to wait until their disease has worsened - and lung function has been lost - before getting routine NHS access to the drug. “This is an illogical decision, to deny effective treatment in a condition that is irreversibly progressive and ultimately fatal,” said Dr Toby Maher, consultant physician at the Royal Brompton Hospital....